NTLA

#2074
Intellia Therapeutics, Inc
14.7800 USD
+3.65%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
14.7800
14.7800
Jahresspanne
7.9500
17.0900
Tagesänderung
+3.65%
Monatliche Änderung
+12.65%
6 month change
+7.73%
Jahresänderung
+7.73%
Vorheriger Schlusskurs
14.2600
Eröffnung
14.7800
Bid
Ask
Tief
14.7800
High
14.7800
Volumen
95
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 1.746 B
  • Employee 377
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-2.36
Preis-Umsatz-Verhältnis
14.4

Intellia Therapeutics Inc

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

Nachrichten